We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Hydroxycitrate Potentially More Effective Than Citrate for Kidney Stones

By LabMedica International staff writers
Posted on 18 Aug 2016
The chemical hydroxycitrate (HCA) was shown in a recent study to be more effective for treating calcium oxalate kidney stones than the commonly used compound potassium citrate.

Calcium oxalate monohydrate is the principal component of human kidney stones and citrate (CA) is an often-used therapy, but hydroxycitrate (HCA) is not. More...
In a study published in the August 8, 2016, online edition of the journal Nature, investigators at the University of Houston (TX, USA) used techniques of bulk crystallization, in situ atomic force microscopy, and density functional theory to compare the capacity of CA and HCA to prevent or even reverse the growth of calcium oxalate crystals.

The investigators reported finding a mechanism that differed from classical theory in that inhibitor adsorption on crystal surfaces induced dissolution of the crystal under specific conditions rather than merely reducing the rate of crystal growth. This phenomenon occurred even in supersaturated solutions where the inhibitor concentration was three orders of magnitude less than that of the solute.

Decrease in crystal size was explained by a hypothesis, generated from atomic force microscopy observations, that inhibitor–crystal interactions imparted localized strain to the crystal lattice and that oxalate and calcium ions were released into solution to alleviate this strain.

For HCA to function as a kidney stone treatment, it must be excreted in urine. The investigators reported that HCA ingested by non-stone-forming humans at an often-recommended dose led to substantial urinary excretion. In vitro assays using human urine revealed that HCA was as effective an inhibitor of nucleation of calcium oxalate monohydrate nucleation as was CA. These findings supported further exploration of the clinical potential of hydroxycitrate as an alternative treatment to citrate for kidney stones.

Senior author Dr. Jeffrey D. Rimer, associate professor of chemical engineering at the University of Houston, said that, "While this research established the groundwork to design an effective drug, questions remain. Long-term safety, dosage, and additional human trials are needed. But our initial findings are very promising. If it works in vivo, similar to our trials in the laboratory, HCA has the potential to reduce the incidence rate of people with chronic kidney stone disease."

Related Links:
University of Houston


Gold Member
Serological Pipets
INTEGRA Serological Pipets
Collection and Transport System
PurSafe Plus®
New
Hemodynamic System Monitor
OptoMonitor
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.